The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak- A n update on the status

Military Medical Research

Volumn 7, Issue 1, 2020, Pages

  Guo, Yan Rong ^a   Cao, Qing Dong ^b   Hong, Zhong Si ^b   Tan, Yuan Yang ^a   Chen, Shou Deng ^a   Jin, Hong Jun ^a   Tan, Kai Sen ^c   Wang, De Yun ^c   Yan, Yan ^a,b  

^a Guangdong Provincial Engineering Research Center of Molecular Imaging   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Clinical characteristics; Coronavirus disease 2019 (COVID 19); Origin; SARS CoV 2; Therapy; Transmission

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; ARBIDOL; CHINESE MEDICINAL FORMULA; CHLOROQUINE; FAVIPIRAVIR; GANCICLOVIR; IMMUNOGLOBULIN G; LOPINAVIR PLUS RITONAVIR; NAFAMSTAT; NITAZOXANIDE; OSELTAMIVIR; PENCICLOVIR; REMDESIVIR; RIBAVIRIN; SHUFENG JIEDU; UNCLASSIFIED DRUG; ANGIOTENSIN CONVERTING ENZYME 2; COVID-19; DIPEPTIDYL CARBOXYPEPTIDASE; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; VIRUS ENVELOPE PROTEIN;

ANTIVIRAL THERAPY; CHINA; CLINICAL FEATURE; CLINICAL OUTCOME; CORONAVIRUS DISEASE 2019; CORONAVIRUS INFECTION; EPIDEMIC; EXTRACORPOREAL OXYGENATION; GENE STRUCTURE; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; NONHUMAN; PLASMA TRANSFUSION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; SYMPTOM; VIRUS GENOME; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION; VIRUS VIRULENCE; ADULT; AGED; ALPHACORONAVIRUS; ANIMAL; BAT; BETACORONAVIRUS; COUGHING; DIARRHEA; DISEASE CARRIER; FATIGUE; FEMALE; FEVER; GENETICS; MALE; MIDDLE AGED; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PATHOGENICITY; SARS CORONAVIRUS; VIRULENCE; VIRUS PNEUMONIA;

ADULT; AGED; ALPHACORONAVIRUS; ANIMALS; BETACORONAVIRUS; CHINA; CHIROPTERA; CORONAVIRUS INFECTIONS; COUGH; DIARRHEA; DISEASE OUTBREAKS; DISEASE RESERVOIRS; FATIGUE; FEMALE; FEVER; HUMANS; MALE; MIDDLE AGED; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PEPTIDYL-DIPEPTIDASE A; PNEUMONIA, VIRAL; SARS VIRUS; VIRAL ENVELOPE PROTEINS; VIRULENCE; VIRUS REPLICATION;

EID: 85082093259     PISSN: 20957467     EISSN: 20549369     Source Type: Journal    
DOI: 10.1186/s40779-020-00240-0     Document Type: Review

References (105)

1. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-74.
2. WHO. Coronavirus disease (COVID-2019) situation reports. 2020. http://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed 5 Mar 2020.
3. Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Euro Surveill. 2020;25(4):2000058. http://doi.org/10.2807/1560-7917.ES.2020.25.4.2000058.
4. Liu Y, Gayle AA, Wilder-Smith A, Rocklov J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. 2020. http://doi.org/10.1093/jtm/taaa021.
5. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. Lancet. 2020;395(10223):514-23.
6. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33.
7. Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018;23(2):130-7.
8. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020. http://doi.org/10.1038/s41586-020-2012-7.
9. Giovanetti M, Benvenuto D, Angeletti S, Ciccozzi M. The first two cases of 2019-nCoV in Italy: Where they come from? J Med Virol. 2020:1-4. http://doi.org/10.1002/jmv.25699 [Epub ahead of print].
10. Paraskevis D, Kostaki EG, Magiorkinis G, Panayiotakopoulos G, Sourvinos G, Tsiodras S. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect Genet Evol. 2020;79:104212.
11. Hampton T. Bats may be SARS reservoir. JAMA. 2005;294(18):2291.
12. Banerjee A, Kulcsar K, Misra V, Frieman M, Mossman K. Bats and coronaviruses. Viruses. 2019;11(1):E41. http://doi.org/10.3390/v11010041.
13. Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science. 2005;310(5748):676-9.
14. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020. http://doi.org/10.1038/s41586-020-2008-3 [Epub ahead of print].
15. Liu Z, Xiao X, Wei X, Li J, Yang J, Tan H, et al. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. J Med Virol. 2020. http://doi.org/10.1002/jmv.25726 [Epub ahead of print].
16. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020. http://doi.org/10.1056/NEJMoa2002032.
17. Chowell G, Abdirizak F, Lee S, Lee J, Jung E, Nishiura H, et al. Transmission characteristics of MERS and SARS in the healthcare setting: A comparative study. BMC Med. 2015;13:210.
18. Kang CK, Song KH, Choe PG, Park WB, Bang JH, Kim ES, et al. Clinical and epidemiologic characteristics of spreaders of middle east respiratory syndrome coronavirus during the 2015 outbreak in Korea. J Korean Med Sci. 2017;32(5):744-9.
19. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: Recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523-34.
20. Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, et al. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses. 2019;11(1):E59. http://doi.org/10.3390/v11010059.
21. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181-92.
22. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020. http://doi.org/10.1016/j.chom.2020.02.001 [Epub ahead of print].
23. Angeletti S, Benvenuto D, Bianchi M, Giovanetti M, Pascarella S, Ciccozzi M. COVID-2019: The role of the nsp2 and nsp3 in its pathogenesis. J Med Virol. 2020. http://doi.org/10.1002/jmv.25719.
24. Zhang L, Shen FM, Chen F, Lin Z. Origin and evolution of the 2019 novel coronavirus. Clin Infect Dis. 2020. http://doi.org/10.1093/cid/ciaa112 [Epub ahead of print].
25. Wu D, Zou S, Bai T, Li J, Zhao X, Yang L, et al. Poultry farms as a source of avian influenza a (H7N9) virus reassortment and human infection. Sci Rep. 2015;5:7630.
26. Tang X, Wu C, Li X, Song Y, Yao X, Wu X, et al. On the origin and continuing evolution of SARS-CoV-2. Natl Sci Rev. 2020. http://doi.org/10.1093/nsr/nwaa036.
27. Jia HP, Look DC, Shi L, Hickey M, Pewe L, Netland J, et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol. 2005;79(23):14614-21.
28. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. J Virol. 2020. http://doi.org/10.1128/JVI.00127-20 [Epub ahead of print].
29. Tortorici MA, Veesler D. Structural insights into coronavirus entry. Adv Virus Res. 2019;105:93-116.
30. Zhang N, Jiang S, Du L. Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev Vaccines. 2014;13(6):761-74.
31. Xia S, Zhu Y, Liu M, Lan Q, Xu W, Wu Y, et al. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol. 2020. http://doi.org/10.1038/s41423-020-0374-2.
32. Yu F, Du L, Ojcius DM, Pan C, Jiang S. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect. 2020. http://doi.org/10.1016/j.micinf.2020.01.003 [Epub ahead of print].
33. de Wilde AH, Snijder EJ, Kikkert M, van Hemert MJ. Host factors in coronavirus replication. Curr Top Microbiol Immunol. 2018;419:1-42.
34. Sawicki SG, Sawicki DL. Coronavirus transcription: A perspective. Curr Top Microbiol Immunol. 2005;287:31-55.
35. Hussain S, Pan J, Chen Y, Yang Y, Xu J, Peng Y, et al. Identification of novel subgenomic RNAs and noncanonical transcription initiation signals of severe acute respiratory syndrome coronavirus. J Virol. 2005;79(9):5288-95.
36. Perrier A, Bonnin A, Desmarets L, Danneels A, Goffard A, Rouille Y, et al. The C-terminal domain of the MERS coronavirus M protein contains a trans-Golgi network localization signal. J Biol Chem. 2019;294(39):14406-21.
37. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020. http://doi.org/10.1038/s41564-020-0688-y.
38. Song W, Gui M, Wang X, Xiang Y. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLoS Pathog. 2018;14(8):e1007236.
39. Millet JK, Whittaker GR. Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis. Virus Res. 2015;202:120-34.
40. Simmons G, Gosalia DN, Rennekamp AJ, Reeves JD, Diamond SL, Bates P. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. P Natl Acad Sci USA. 2005;102(33):11876-81.
41. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020. http://doi.org/10.1056/NEJMoa2001316 [Epub ahead of print].
42. Lee PI, Hsueh PR. Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV. J Microbiol Immunol Infect. 2020. http://doi.org/10.1016/j.jmii.2020.02.001 [Epub ahead of print].
43. Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, et al. Molecular and serological investigation of 2019-nCoV infected patients: Implication of multiple shedding routes. Emerg Microbes Infect. 2020;9(1):386-9.
44. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631-7.
45. Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020;7(1):4.
46. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020. http://doi.org/10.1001/jama.2020.1585 [Epub ahead of print].
47. Poutanen SM, Low DE, Henry B, Finkelstein S, Rose D, Green K, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med. 2003;348(20):1995-2005.
48. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
49. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol. 2020;92(4):401-2.
50. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395(10223):507-13.
51. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348(20):1986-94.
52. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: A descriptive study. Lancet Infect Dis. 2013;13(9):752-61.
53. Wang H, Xiao X, Lu J, Chen Z, Li K, Liu H, et al. Factors associated with clinical outcome in 25 patients with avian influenza a (H7N9) infection in Guangzhou, China. BMC Infect Dis. 2016;16(1):534.
54. Kui L, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J. 2020. http://doi.org/10.1097/CM9.0000000000000744 [Epub ahead of print].
55. Chung M, Bernheim A, Mei X, Zhang N, Huang M, Zeng X, et al. CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology. 2020;200230. http://doi.org/10.1148/radiol.2020200230. [Epub ahead of print].
56. Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol. 2020;92(4):441-7.
57. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med. 2020. http://doi.org/10.1016/s2213-2600(20)30079-5.
58. Gao HN, Lu HZ, Cao B, Du B, Shang H, Gan JH, et al. Clinical findings in 111 cases of influenza a (H7N9) virus infection. N Engl J Med. 2013;368(24):2277-85.
59. Wang J, Qi H, Bao L, Li F, Shi Y, National Clinical Research Center for Child H, et al. A contingency plan for the management of the 2019 novel coronavirus outbreak in neonatal intensive care units. Lancet Child Adolesc Health. 2020. http://doi.org/10.1016/S2352-4642(20)30040-7 [Epub ahead of print].
60. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by toll-like receptor 3. Nature. 2001;413(6857):732-8.
61. Wu J, Chen ZJ. Innate immune sensing and signaling of cytosolic nucleic acids. Annu Rev Immunol. 2014;32:461-88.
62. Yoo JS, Kato H, Fujita T. Sensing viral invasion by RIG-I like receptors. Curr Opin Microbiol. 2014;20:131-8.
63. Wu J, Sun L, Chen X, Du F, Shi H, Chen C, et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science. 2013;339(6121):826-30.
64. Seth RB, Sun L, Ea CK, Chen ZJ. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell. 2005;122(5):669-82.
65. Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature. 2008;455(7213):674-8.
66. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: Update on toll-like receptors. Nat Immunol. 2010;11(5):373-84.
67. Takeuchi O, Akira S. Innate immunity to virus infection. Immunol Rev. 2009;227(1):75-86.
68. Chen C, Zhang XR, Ju ZY, He WF. Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies. Zhonghua Shaoshang Zazhi. 2020;36(0):E005.
69. Liu Y, Zhang C, Huang F, Yang Y, Wang F, Yuan J, et al. 2019-novel coronavirus (2019-nCoV) infections trigger an exaggerated cytokine response aggravating lung injury. 2020. http://www.chinaxiv.org/abs/202002.00018. Accessed 18 Feb 2020.
70. Liu Q, Wang R, Qu G, Wang Y, Liu P, Zhu Y, et al. General anatomy report of novel coronavirus pneumonia death corpse. J Forensic Med. 2020;36(1):19-21.
71. National Health Commission of the People's Republic of China. Diagnosis and Treatment of Pneumonia Caused by 2019-nCoV (version 6). 2020. http://www.gov.cn/zhengce/zhengceku/2020-02/19/content-5480948.htm. Accessed 18 Feb 2020.
72. WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed 28 Jan 2020.
73. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020. http://doi.org/10.1016/s1473-3099(20)30141-9.
74. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses-drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327-47.
75. Li H, Wang YM, Xu JY, Cao B. Potential antiviral therapeutics for 2019 Novel Coronavirus. Chin J Tuberc Respir Dis. 2020;43(0):E002.
76. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus susceptibility to the antiviral remdesivir (gs-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9(2):e00221-18. http://doi.org/10.1128/mBio.00221-18.
77. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020. http://doi.org/10.1056/NEJMoa2001191 [Epub ahead of print].
78. Aguiar ACC, Murce E, Cortopassi WA, Pimentel AS, Almeida M, Barros DCS, et al. Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity. Int J Parasitol Drugs Drug Resist. 2018;8(3):459-64.
79. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: An old drug against today's diseases? Lancet Infect Dis. 2003;3(11):722-7.
80. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69.
81. Golden EB, Cho HY, Hofman FM, Louie SG, Schonthal AH, Chen TC. Quinoline-based antimalarial drugs: A novel class of autophagy inhibitors. Neurosurg Focus. 2015;38(3):E12.
82. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020. http://doi.org/10.1038/s41422-020-0282-0 [Epub ahead of print].
83. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: A review of its use in the management of HIV infection. Drugs. 2003;63(8):769-802.
84. Arabi YM, Asiri AY, Assiri AM, Aziz Jokhdar HA, Alothman A, Balkhy HH, et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): Statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. Trials. 2020;21(1):8.
85. Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax. 2004;59(3):252-6.
86. Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: The application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020;35(6):e79.
87. Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020. c [Epub ahead of print].
88. Tchesnokov EP, Feng JY, Porter DP, Gotte M. Mechanism of inhibition of ebola virus rna-dependent rna polymerase by remdesivir. Viruses. 2019;11(4):E326. http://doi.org/10.3390/v11040326.
89. Lo MK, Feldmann F, Gary JM, Jordan R, Bannister R, Cronin J, et al. Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. Sci Transl Med. 2019;11(494):eaau9242. http://doi.org/10.1126/scitranslmed.aau9242.
90. Hsieh HP, Hsu JT. Strategies of development of antiviral agents directed against influenza virus replication. Curr Pharm Des. 2007;13(34):3531-42.
91. Nishimura H, Yamaya M. A synthetic serine protease inhibitor, Nafamostat Mesilate, is a drug potentially applicable to the treatment of ebola virus disease. Tohoku J Exp Med. 2015;237(1):45-50.
92. PAAASLD-IDSA H Guidance & Panel. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2018;67(10):1477-92.
93. Tsang K, Zhong NS. SARS: Pharmacotherapy. Respirology. 2003;8(Suppl 1):S25-30.
94. Arabi YM, Shalhoub S, Mandourah Y, Al-Hameed F, Al-Omari A, Al Qasim E, et al. Ribavirin and interferon therapy for critically ill patients with middle east respiratory syndrome: A multicenter observational study. Clin Infect Dis. 2019. http://doi.org/10.1093/cid/ciz544 [Epub ahead of print].
95. McQuade B, Blair M. Influenza treatment with oseltamivir outside of labeled recommendations. Am J Health. 2015;72(2):112-6.
96. Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: Systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348:g2545.
97. Shiraki K. Antiviral drugs against alphaherpesvirus. Adv Exp Med Biol. 2018;1045:103-22.
98. Al-Badr AA, Ajarim TDS. Ganciclovir. Profiles Drug Subst Excip Relat Methodol. 2018;43:1-208.
99. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivir Res. 2013;100(2):446-54.
100. Goldhill DH, Te Velthuis AJW, Fletcher RA, Langat P, Zambon M, Lackenby A, et al. The mechanism of resistance to favipiravir in influenza. P Natl Acad Sci USA. 2018;115(45):11613-8.
101. Cardile AP, Warren TK, Martins KA, Reisler RB, Bavari S. Will there be a cure for Ebola? Annu Rev Pharmacol. 2017;57:329-48.
102. Rossignol JF. Nitazoxanide: A first-in-class broad-spectrum antiviral agent. Antivir Res. 2014;110:94-103.
103. Cao J, Forrest JC, Zhang X. A screen of the NIH clinical collection small molecule library identifies potential anti-coronavirus drugs. Antivir Res. 2015;114:1-10.
104. Rossignol JF. Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health. 2016;9(3):227-30.
105. Kang L, Li Y, Hu S, Chen M, Yang C, Yang BX, et al. The mental health of medical workers in Wuhan, China dealing with the 2019 novel coronavirus. Lancet Psychiatry. 2020;7(3):e14.